Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology
Morgan Stanley Looks Over Celgene's Quarter
Stock Market News for May 06, 2015 - Market News (Zacks)

In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.

Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Jan 2015CitigroupMaintainsBuy
Jan 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters